Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-Derived Tumor Organoid Drug Sensitivity Testing to Guide Treatment Selection in Patients With Unresectable Hepatocellular Carcinoma
NCT07351513Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jan 2026
- Primary completion
- Oct 2026
01
Overview
Phase 2, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Objective Response Rate up to 4 years and Progression-Free Survival up to 4 years. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07351513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07351513.